ABSTRACT

We report a unique case of metastatic malignant teratoma from an undescended testis which presented with acute pulmonary embolism. After chemotherapy, the undescended right testicle was resected along with a cord of non-obstructing inferior venal caval tumour which extended into the right atrium with tumour floating free within the atrium at the end of the cord of tumour. The presentation, diagnosis and treatment of testicular tumours is described and the literature pertaining to testicular tumours in military personnel reviewed.

Case Report

A 21 year old civilian male presented to accident and emergency with chest pain and shortness of breath. On examination he was tachycardic, tachypnoeic and hypoxic on room air. On chest auscultation he had globally poor air entry, but no wheeze or focal abnormality. Plain chest radiography showed possible “cannon ball” lung metastases as well as atelectasis, pleural ‘wedge-shape’ densities and blunting of the costophrenic angles, all suggestive of pulmonary embolism. A provisional diagnosis of pulmonary embolism secondary to metastatic malignancy was made and the patient commenced on therapeutic dose low molecular weight heparin. On further clinical examination, despite normal secondary sexual characteristics and a left-sided incision from a childhood groin exploration there was no evidence of scrotal or inguinal testes.

Thoracoabdominal CT scanning confirmed lung metastases (Figure 1) and revealed a suspicious liver lesion, abdominal and pelvic lymphadenopathy and bilateral intra-abdominal testes. Initial tumour marker concentrations were grossly elevated: ß-human chorionic gonadotrophin (ß-HCG) 19,079 mIU/ml (<5 mIU/ml), ð-fetoprotein (ð-FP) 6,250 ng/ml (<5 ng/ml) and lactate dehydrogenase (LDH) 2,000 IU/L (60-225 IU/L). Although there was no formal histological confirmation, the tumours markers, clinical findings and abdominal CT strongly suggested a diagnosis of metastatic non-seminomatous germ cell tumour (NSGCT).

His poor prognosis tumour (Stage T3NxM1b - predicting 48% 5 year survival (1)) was treated with 4 cycles of bleomycin etoposide cisplatin (BEP) chemotherapy according to current guidelines (2), which returned his tumour markers to normal levels. A repeat CT scan showed regression of his liver and lung lesions, however there was a residual 6cm x 6cm mass in the right pelvis. Surgical resection of residual masses after chemotherapy for NSGCT is recommended when tumour marker levels are normal (3). Preoperative review of his CT scans suggested an additional abnormal lucency in his right atrium, thought possibly to be a thrombus. At operation the residual pelvic mass was an enlarged right testicle at the pelvic brim, just proximal to the internal inguinal ring. After removal of the right testicle its vessels were followed to an area of dense necrotic lymphadenopathy in the inter-aorto-caval region which was also removed. A fibrous ‘tether’ was found to extend upwards from the insertion of the right testicular vein (Figure 2 - black arrow), to within the vena cava. Gentle traction was applied and delivered a 16cm thrombus with a 3cm x 1.5 cm mass at its end (Figure 2 - white arrow), consisting of necrotic tumour embolus that had been floating in the right atrium. In addition, the patient underwent excision of a necrotic deposit in his liver and an atrophic undescended left testis. Histological examination of the right testes revealed predominantly necrotic tumour with some foci of differentiated teratoma and undifferentiated embryonal carcinoma. The left testes showed no evidence of cancer or carcinoma-in-situ.
Discussion

Testicular cancer is rare, accounting for only 1% of male cancers in the United Kingdom (UK), but it is the most common solid tumour affecting men in 15-35 year-old age range, with an incidence, which is increasing in both the civilian and military population, of 3-6 cases annually per 100,000 males (4-6). In the UK this equates to approximately 1400 new cases diagnosed per year. In the Armed Forces, it is the commonest malignancy after lymphoma (7). This case represents a rare presentation of testicular malignancy but as the average age of active duty personnel is included in the age range of those most at risk of testicular cancer, it is important that military physicians are aware of both the common and more esoteric presentations of testicular cancer (7,8). Our case represents the first report of a patient with a testicular tumour presenting with a non-obstructing vena caval thrombus with tumour attached to its free end floating in the right atrium.

The commonest presentation of testicular cancer is painless enlargement of the testicle (4, 9), whilst approximately 10% present with an acute scrotum, probably due to intratesticular haemorrhage or infarction (9,10). It may also be diagnosed after an episode of trauma because it brings the underlying tumour to the attention of the physician (11). Around 10% of all testis tumours occur in undescended testes. Cryptorchid testes have a 3-5% chance of developing cancer, with intra-abdominal testes having the highest risk of malignant transformation (5). Around 10% of patients will present with symptoms of metastatic disease. The commonest sites for secondary spread are lung (89%) giving dyspnoea or cough, liver (73%), kidney (31%), bone (30%) and brain (30%) (12) although a plethora of rarer presentations have all been reported (13-18).

Testicular cancer metastasis to the retroperitoneum can present with a number of complications due to invasion or obstruction of adjacent structures (19), including inferior vena cava obstruction (IVC), commoner with right sided tumours and associated with symptomatic pulmonary embolism in 29% (20, 21). IVC thrombosis from a testicular tumour, intracaval floating NSGCT, propagation of IVC thrombus into the right atrium with free-floating thrombus, and metastases to the tricuspid valve by haematogenous spread (22-26) have all been reported. Non-obstructing IVC thrombus with tumour floating in the right atrium at its free end has not previously been described. Pulmonary embolism as a complication of metastatic testicular cancer is well documented and may be the cause of sudden unexpected death in affected young men (19, 27, 28), with emboli developing from a combination of IVC invasion and hypercoagulability of malignancy (12). The management options for vena cava thrombosis complicating metastatic testicular tumour, include anticoagulation, chemotherapeutic cytoreduction, inferior vena caval filters and retroperitoneal tumour resection with en bloc resection of the IVC (20, 27, 29, 30).

Fig 2. Right testicle showing termination of testicular vein (black arrow) and intracaval thrombus, which extended into the right atrium, with tumour embolus at its end (white arrow).

Diagnosis and Treatment

After finding a suspicious scrotal lesion the spermatic cord and scrotal skin should be checked for involvement, as well as the contralateral testes and the abdomen, chest and cervical regions for signs of metastases (10). Scrotal ultrasound confirms the presence of an intratesticular mass and serum tumour markers (a-fetoprotein, ß-HCG and LDH) should be measured. Radiological staging requires CT of the chest, abdomen and pelvis (2). Radical inguinal orchidectomy remains the standard for diagnosis, provision of a detailed pathological analysis, staging and treatment of testicular neoplasms (31, 32).

The further treatment of testicular cancer depends on tumour histology and stage and the wishes and motivation of the patient (3, 32). The commonest staging system is that of the Royal Marsden Hospital which classifies tumours into four broad stages (32). Patients with advanced tumours are treated with primary chemotherapy. Patients with lower stage tumours undergo orchidectomy and then either put on surveillance, receive chemotherapy or radiotherapy or further surgery to retroperitoneal lymph nodes. Survival rates are high and with the application of multimodal therapy including effective chemotherapeutic regimes, cure rates of more than 95% can be achieved (33). For stage 1 seminomas and NSGCT’s cure rates approach 100%, reinforcing the fact that the earlier a testicular tumour is diagnosed and treated, the better.
Testicular cancer in the military and the role of self examination

Studies of servicemen with testicular cancer have shown that blame for delay in diagnosis is shared by the patient, general practitioners and hospital specialist. (7,34). The typical delay in treatment from recognition of the lesion by the patient to definitive therapy ranges from 3-6 months and correlates with the incidence of metastases (9). Price et al in a large study of 140 testicular cancers treated by the Army Medical Services showed that 44% of cases had primary treatment delayed by more than one month because of men’s failure to report symptoms (7). The study did not comment if the delay was because of the men’s embarrassment in seeking help or lack of knowledge, however testicular health promotion could alleviate both problems. The authors also noted that 16% of cases had treatment delayed by the same period because of slow referral. This emphasises the fact that all medical officers should be vigilant of possible testicular tumours and aware of the appropriate management and referral pathways. Although recent diagnostic and therapeutic developments have greatly improved the prognosis in this disease, continued delay in diagnosis will impact on further possible improvements in survival. Screening for testicular cancer is not recommended as the overall incidence of testicular cancer is low and survival excellent. Testicular self examination (TSE) and testicular health awareness is, however, promoted by the major cancer charities although the evidence to support TSE is scarce. It may provoke unwarranted anxiety and unnecessary medical interventions (35), although other authors suggest providing more information on testicular cancer and TSE may reduce the number of men requiring toxic treatment and major surgery and may even reduce mortality (36). Certainly improving health awareness and teaching TSE in at risk groups may be beneficial and studies suggest most men would be willing participants (37). An Israeli army study reported that few soldiers are shown TSE, only 2% practised it regularly and 24% had never examined their testicles before (38). In the same study army physicians were questioned about physical examinations they carried out on soldiers, and of 200 questioned, only 10% routinely examined testicles.

Research has indicated that most men do not know the importance of TSE, and confirms the need for both patient education and physician awareness of the potential seriousness of all testicular masses or adult cryptorchidism (12, 39).

Conclusion

The military medical officer should take advantage of entrance and routine medicals to check for undescended or abnormal testicles and to improve patient awareness of testicular cancer and teach testicular self examination. Our case, although reporting a unique presentation of the disease, highlights many areas of concern of relevance to physicians caring for a predominantly male service population. Physicians are reminded that vague presentations of ill health in males should prompt examination of the external genitalia, and that an empty scrotum should be investigated in the absence of a clear history of orchidectomy.

References


An Unusual Presentation Of Metastatic Testicular Tumour

S J Barton, DA Ashdown, S Ganta and Michael Wallace

*J R Army Med Corps* 2005 151: 30-33
doi: 10.1136/jramc-151-01-05

Updated information and services can be found at:
[http://jramc.bmj.com/content/151/1/30](http://jramc.bmj.com/content/151/1/30)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)